Why the study?
Does dabigatran etexilate prevent venous thromboembolic complications effectively compared to parenteral direct anticoagulants followed by vitamin K antagonists in patients with lower extremity long bone fractures?
Does dabigatran etexilate prevent venous thromboembolic complications effectively compared to parenteral direct anticoagulants followed by vitamin K antagonists in patients with lower extremity long bone fractures?
Dabigatran etexilate provides effective anticoagulation without the need for routine monitoring for VTE prophylaxis in patients with lower extremity long bone fractures.
Answers are grounded in this paper and cite their sources.
May support dabigatran for VTE prophylaxis without monitoring in fracture patients; leaves open need for RCTs versus standard regimens.
Complex dynamic examination of 68 patients with fractures of lower extremities long bones. In first comparative group (36 patients, mean age 36.3±1.4 years) prevention of thromboembolic complications was performed with parenteral direct anticoagulants followed by vitamin K antagonists. In second group (32 patients, mean age 39.3±2.0 years) dabigatran etexilate was used. Duration of anticoagulant therapy made up 30 days. It was noted that in fractures of long bones of the extremities application of dabigatran etexilate ensured effective, prognosticating, stable anticoagulant action and did not require routine control of coagulation parameters that enabled to recommend that drug for wider use in trauma and orthopaedic patients.
No takes yet. Share an insight, caveat, or question.
А. М. Мироманов (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: